Pregnenolone: The Hormone Precursor Behind Progesterone, Cortisol, and More

From World War II aviation research to arthritis treatments and modern discoveries about the brain, pregnenolone has a fascinating and often overlooked history.

During World War II, researchers investigating fatigue and mental performance became interested in an unusual substance called pregnenolone. Their experiments suggested that this naturally occurring steroid might help people maintain coordination and performance under demanding conditions. Around the same time, physicians began investigating pregnenolone as a possible treatment for rheumatoid arthritis. For a brief period, it appeared that this relatively obscure hormone precursor might have an important future in medicine.

More than 80 years later, pregnenolone remains intriguing, although many of its proposed clinical benefits are still being investigated. Its scientific importance, however, is beyond question. Pregnenolone sits at the beginning of the steroid hormone pathway, serving as the starting material for progesterone, cortisol, DHEA, testosterone, estrogen, and several other biologically important compounds.

Sometimes called the mother of steroid hormones, pregnenolone is not simply an inert precursor waiting to be converted into something else. It and its metabolites participate in complex signaling systems, particularly in the nervous system. Research has explored their possible roles in memory, mood, stress adaptation, and pain perception. Equally interesting are the relationships between pregnenolone production, thyroid function, vitamin A signaling, and the body’s response to chronic stress.

Understanding pregnenolone therefore offers a fascinating window into the interconnected world of steroid hormones—and raises questions about hormone production, aging, and whether supplementation can provide meaningful clinical benefits.

Where Is Pregnenolone Made in the Body?

Pregnenolone is produced from cholesterol, a substance often discussed exclusively in the context of cardiovascular disease but essential to normal human physiology. Cholesterol supplies the structural foundation for every steroid hormone the body manufactures. Without it, there would be no progesterone, cortisol, testosterone, or estrogen.

The conversion of cholesterol into pregnenolone occurs inside mitochondria, the cellular structures best known for their role in energy production. In major steroid-producing cells, a protein called StAR (steroidogenic acute regulatory protein) facilitates the movement of cholesterol into the mitochondria. There, an enzyme known as CYP11A1, or cholesterol side-chain cleavage enzyme, converts cholesterol into pregnenolone. This is the first enzymatic step in steroid hormone synthesis. [1]

The adrenal glands are important sites of pregnenolone production, using it to manufacture cortisol, aldosterone, and adrenal androgen precursors. The ovaries produce pregnenolone for the synthesis of progesterone and other reproductive hormones, while the testes use it in pathways leading to testosterone production. During pregnancy, the placenta also produces substantial amounts of progesterone through pregnenolone-dependent steroidogenesis.

Perhaps less widely appreciated is that steroid synthesis is not confined to the traditional endocrine glands. Certain cells in the brain and nervous system possess the biochemical machinery needed to produce pregnenolone locally. Steroidogenic activity has also been identified in the skin. These findings are important because locally produced steroids can have effects within the tissues where they are synthesized, without necessarily entering the general circulation in substantial amounts. [1, 2]

This distinction helps explain why pregnenolone cannot be understood simply by measuring its concentration in the bloodstream. The body does not operate with one common pool of pregnenolone that every organ draws upon equally. Production, conversion, and biological activity are regulated according to the needs and enzymatic capabilities of individual tissues.

From Pregnenolone to Progesterone, Cortisol, and Sex Hormones

Once pregnenolone has been formed, it can enter several steroidogenic pathways. One of the most important involves conversion to progesterone through the enzyme 3β-hydroxysteroid dehydrogenase. Progesterone is itself a major hormone, but in certain tissues it can also serve as an intermediate in the multistep synthesis of cortisol and aldosterone. Pregnenolone can alternatively be converted to 17-hydroxypregnenolone and then DHEA, contributing to the production of androgens and, ultimately, estrogens.

These pathways are not interchangeable assembly lines. Each conversion requires particular enzymes, and their activity varies substantially between the adrenal glands, ovaries, testes, placenta, and other tissues. The adrenal cortex, for example, possesses specialized enzyme systems that enable cortisol production, whereas the corpus luteum is particularly adapted for progesterone synthesis.

For this reason, taking pregnenolone does not guarantee a corresponding increase in progesterone, cortisol, or any other specific downstream hormone. The actual hormonal response depends on where the pregnenolone is metabolized, which enzymes are available, and how the body’s endocrine feedback systems respond.

This is particularly important when discussing progesterone therapy. Pregnenolone may be progesterone’s biochemical parent, but the two compounds are not therapeutically interchangeable. Their biological activities differ, and supplying a precursor cannot be assumed to reproduce the effects of administering progesterone directly.

Vitamin A: An Overlooked Connection to Pregnenolone Production

Vitamin A is usually associated with eyesight, immune function, and healthy skin. Its role in reproduction and cellular differentiation is also well established, but its potential involvement in steroid hormone production receives comparatively little attention.

Vitamin A acts partly through derivatives known as retinoids, including retinoic acid. These molecules interact with nuclear receptors that regulate gene expression, influencing how cells develop, differentiate, and perform specialized functions. Because steroid hormone production depends on carefully regulated enzyme systems, researchers have investigated whether retinoid signaling might influence the machinery responsible for manufacturing pregnenolone.

A particularly interesting investigation was published in 2015 by Manna and colleagues in Mechanisms of Ageing and Development. Using laboratory models that included adrenal, ovarian, glial, and skin-derived cells, the researchers explored how retinoid signaling affected StAR expression and steroid synthesis. They found that retinoid treatment could increase StAR expression and steroidogenic activity in several experimental systems. In selected neural and skin cell models, retinoid treatment also increased measured pregnenolone synthesis under experimental conditions that limited its further metabolism. [2]

The significance is that StAR helps govern one of the earliest steps in steroid production: the movement of cholesterol into mitochondria. Increasing the activity of this system can, under appropriate experimental conditions, increase the availability of cholesterol for conversion into pregnenolone.

These findings suggest a potentially important connection between vitamin A signaling and the body’s steroidogenic capacity. However, the research was conducted primarily in cultured cells and experimental models, not in people taking vitamin A supplements. It does not establish that additional vitamin A will raise pregnenolone concentrations or improve hormonal symptoms in individuals who already have adequate vitamin A status.

There is also an important safety consideration. Vitamin A is fat-soluble, and excessive intake of preformed vitamin A can produce toxicity. The National Institutes of Health identifies an adult tolerable upper intake level of 3,000 micrograms of retinol activity equivalents per day for preformed vitamin A, equivalent to approximately 10,000 IU of retinol. This is a safety limit, not a recommended daily intake, and excess preformed vitamin A is particularly concerning during pregnancy because of its potential to cause birth defects. [3]

The most useful conclusion is not that everyone should take more vitamin A, but that vitamin A signaling deserves recognition as one component of the complex regulation of steroid hormone synthesis.

Thyroid Function and Pregnenolone: The Metabolic Connection

The thyroid gland plays a central role in regulating metabolism, mitochondrial function, and cellular energy production. Thyroid hormones also influence the activity of numerous enzymes and endocrine pathways. It would therefore be reasonable to investigate whether thyroid function affects pregnenolone production or metabolism.

An informative study published in Clinical Chemistry in 2000 examined adrenal steroid concentrations in people with thyroid disorders. Researchers compared 24 patients with hypothyroidism, 22 with hyperthyroidism, and 43 healthy controls. They found that circulating pregnenolone sulfate, DHEA, and DHEA sulfate were lower in hypothyroid patients. In hyperthyroid patients, pregnenolone sulfate and DHEA sulfate were elevated, and several steroid concentrations correlated with thyroid hormone levels. [4]

These observations suggest that thyroid status influences the synthesis, metabolism, or clearance of certain adrenal steroids. One important qualification is that the investigators measured pregnenolone sulfate, not unconjugated pregnenolone. Pregnenolone sulfate is a distinct, biologically active metabolite, particularly relevant to nervous-system signaling. The two compounds should not be treated as identical laboratory measurements.

The relationship becomes even more interesting when vitamin A is considered. Thyroid hormone receptors commonly form partnerships with retinoid X receptors, or RXRs, to regulate gene transcription. RXRs are part of the nuclear receptor signaling system associated with vitamin A derivatives, providing a molecular point of interaction between thyroid hormone activity and retinoid biology. [5]

This does not mean that vitamin A and thyroid hormone work together in a simple formula to increase pregnenolone. Their interactions are complex and depend on cellular context. Nevertheless, they illustrate why steroid hormone production cannot be separated entirely from broader metabolic and nutritional function.

For someone experiencing fatigue, impaired concentration, low mood, or other symptoms sometimes attributed to low pregnenolone, thyroid function is worth evaluating. Correcting a genuine thyroid disorder may be more meaningful than attempting to manipulate one steroid precursor without understanding the underlying endocrine problem.

Pregnenolone, Cortisol, and the Stress Response

Pregnenolone’s relationship to cortisol is especially interesting because cortisol production rises in response to many forms of physical and psychological stress. When the hypothalamic-pituitary-adrenal axis is activated, the pituitary releases adrenocorticotropic hormone, or ACTH, which stimulates steroidogenesis in the adrenal cortex. Cortisol then helps the body respond to increased demands by influencing glucose availability, cardiovascular function, immune responses, and numerous other physiological processes.

Because pregnenolone is an upstream precursor to cortisol, it is tempting to assume that increased cortisol production necessarily consumes pregnenolone and leaves less available for other hormones. This idea lies behind a popular concept in hormone wellness known as pregnenolone steal.

According to the theory, chronic stress increases the body’s demand for cortisol, diverting pregnenolone away from producing progesterone and DHEA. It offers a seemingly straightforward explanation for why chronic stress may coincide with menstrual irregularities, reproductive symptoms, or altered sex hormone concentrations.

There is certainly a well-established relationship between stress and reproductive function. Chronic activation of stress pathways can influence hypothalamic GnRH secretion, pituitary LH and FSH signaling, and hormone production in the ovaries and testes. Glucocorticoids can also exert more direct effects on reproductive tissues. These mechanisms help explain why severe or prolonged stress can disrupt menstrual cycles, ovulation, and reproductive hormone production. [8]

The more specific question is whether these changes occur because cortisol production literally diverts a limited supply of pregnenolone away from progesterone synthesis.

The answer is less certain.

A review by Solano and Arck explored the possibility that stress-related glucocorticoid production could contribute to reduced progesterone availability during pregnancy, including through a proposed pregnenolone-depletion mechanism. The authors explicitly presented this mechanism as a hypothesis rather than an established universal explanation for hormone changes during stress. [7]

The distinction matters because steroid-producing tissues regulate their own cholesterol transport, enzyme activity, and hormone synthesis. There is no convincing basis for assuming that every increase in adrenal cortisol production automatically deprives the ovaries or testes of pregnenolone.

A more accurate description is stress-related disruption of steroidogenesis, which encompasses the various ways stress signals can influence the production and regulation of steroid hormones.

Does Supplemental Pregnenolone Increase Cortisol?

An intriguing clinical observation comes from a 2009 randomized pilot trial by Marx and colleagues involving patients with schizophrenia or schizoaffective disorder. Twenty-one participants were randomized to placebo or pregnenolone, with the pregnenolone dose gradually increased to 500 mg daily during an eight-week study. [6]

In participants who underwent steroid measurements, supplementation substantially increased circulating pregnenolone and several metabolites, including progesterone, allopregnanolone, and pregnenolone sulfate. Yet serum cortisol did not increase significantly. In the measured subgroup, mean cortisol concentrations were approximately 8.08 µg/dL before treatment and 7.96 µg/dL after eight weeks, a difference that was not statistically significant. [6]

These results are particularly interesting because they challenge the assumption that providing additional pregnenolone must automatically increase cortisol. The study was small, however, and the finding should not be generalized to every person, dose, or clinical circumstance.

What it does illustrate is that steroid hormone pathways are regulated. Adding more of an upstream precursor does not mean the body will convert it indiscriminately into every possible downstream product.

World War II: Pregnenolone and the Search for Better Alertness

One of the most remarkable episodes in pregnenolone’s history occurred during the 1940s, when researchers Gregory Pincus and Hudson Hoagland investigated its effects on fatigue and performance.

This was a period when maintaining alertness and coordination under difficult conditions had obvious military and industrial importance. Researchers were interested in whether hormones and related compounds could improve the body’s ability to sustain demanding activity, particularly when fatigue threatened performance.

In 1944, Pincus and Hoagland published Effects of Administered Pregnenolone on Fatiguing Psychomotor Performance in the Journal of Aviation Medicine. Their investigations involved doses of approximately 45–50 mg daily and examined performance during fatiguing tasks. The researchers reported encouraging findings, particularly where performance demands, fatigue, and motivation were important factors. [9]

Hoagland discussed related work in a 1944 Science article titled Adventures in Biological Engineering. The research subsequently extended into industrial settings, with a 1945 publication examining pregnenolone administration and factory-worker performance. [10, 11]

Historical accounts have sometimes transformed these experiments into sweeping claims that pregnenolone was routinely supplied to wartime pilots to keep them alert. The research does have genuine aviation and wartime connections, but routine administration to military pilots has not been established. The early studies also lacked many of the methodological safeguards expected in modern clinical research.

Nevertheless, the historical interest is fascinating. Researchers were exploring the possibility that a naturally occurring steroid precursor might influence performance during fatigue, without relying on the conventional stimulant approach.

Modern investigations have continued to examine pregnenolone’s neurological effects. In 2004, Meieran and colleagues studied oral pregnenolone in healthy volunteers, administering 15 mg daily for two weeks followed by 30 mg daily for another two weeks. Among the study’s findings was an attenuation of benzodiazepine-induced sedation, suggesting that pregnenolone or its metabolites can influence nervous-system responses. [12]

Although neither the wartime investigations nor the later studies establish pregnenolone as a proven treatment for everyday fatigue or poor concentration, they provide an intriguing historical bridge to current neurosteroid research.

Pregnenolone and the Brain: More Than a Hormone Precursor

The nervous system gives pregnenolone an additional dimension that is easy to overlook when discussing it solely as the starting material for other hormones.

Pregnenolone and several of its metabolites are neuroactive steroids, meaning they can influence neuronal signaling. Some may be synthesized locally within nervous-system tissues, while others arise from circulating precursors. Their effects are not identical, because different metabolites interact with different neurotransmitter systems.

Pregnenolone sulfate, for example, influences excitatory and inhibitory signaling, including pathways involving NMDA and GABA-A receptors. Progesterone, meanwhile, can be metabolized to allopregnanolone, a potent positive modulator of GABA-A receptors. Allopregnanolone generally enhances inhibitory neurotransmission, helping explain its interest in research involving mood, stress responses, and nervous-system excitability.

These pathways illustrate an important distinction between pregnenolone and progesterone. Although they are metabolically connected, their effects cannot be reduced to those of a single hormone. Pregnenolone sulfate may influence neuronal excitability differently from progesterone-derived allopregnanolone, and the balance of these metabolites may be important.

Human studies have produced some encouraging but inconsistent findings. In the 2009 schizophrenia pilot trial, pregnenolone was associated with improvement in negative psychiatric symptoms, but the overall cognitive composite scores on two standardized assessment batteries did not differ significantly from placebo. The results therefore did not establish a generalized memory or cognition benefit. [6]

Another randomized trial, published in 2014, examined pregnenolone as an adjunctive treatment for bipolar depression. Eighty adults were randomized to pregnenolone, gradually increased to 500 mg daily, or placebo over 12 weeks. The researchers found a statistically significant treatment-by-week effect on a clinician-rated depression scale, but not on the corresponding self-reported symptom scale. Remission findings also varied depending on the assessment used. [13]

These studies suggest that pregnenolone and its metabolites may influence aspects of nervous-system function, but they do not establish pregnenolone as a treatment for depression, bipolar disorder, cognitive decline, or dementia. The findings remain preliminary, particularly because the evidence comes from relatively small trials with limited independent replication.

Pregnenolone and Arthritis: A Forgotten Chapter in Medical History

Pregnenolone’s historical relationship with arthritis is another fascinating part of its story.

In the late 1940s, the discovery of cortisone’s dramatic anti-inflammatory effects generated tremendous excitement. Cortisone represented a major development in rheumatoid arthritis treatment, but it was difficult to manufacture and carried significant adverse effects. Physicians and researchers began investigating whether related steroids might offer benefits with fewer complications.

Pregnenolone was among the compounds examined. In 1950, Freeman, Pincus, and colleagues published preliminary observations on its therapeutic effectiveness in rheumatoid arthritis in JAMA. Stock and McClure published another investigation in The Lancet, and subsequent research appeared in Annals of the Rheumatic Diseases. [14, 15, 16]

These were genuine clinical investigations, not simply speculative discussions about pregnenolone’s potential. Patients with rheumatoid arthritis received the compound, and researchers observed changes in symptoms, clinical findings, and laboratory markers.

The results, however, were inconsistent. In a 1951 follow-up investigation, Myers and Ross described earlier experience with 10 rheumatoid arthritis patients, of whom two had shown apparent clinical improvement. The improvements were not accompanied by corresponding changes in certain inflammatory measurements. Their subsequent small investigation of four women involved intramuscular or other administration routes, with daily doses that included 300 mg followed by 100 mg. Some subjective improvement was reported, but responses varied and injection-related adverse effects were observed. [16]

By modern standards, these investigations were much too small and methodologically limited to establish reliable therapeutic efficacy. They are nevertheless important historical evidence that pregnenolone was seriously examined as a treatment for inflammatory disease.

The emergence of corticosteroids and, later, more effective disease-modifying therapies shifted medical attention away from pregnenolone. Today, its role in rheumatoid arthritis remains unproven, and the historical studies do not justify substituting it for established arthritis treatments.

A Modern Pain Study Revives Interest

A more recent investigation brought pregnenolone back into the pain literature. In 2020, researchers published a randomized clinical trial in JAMA Network Open examining pregnenolone for chronic low back pain among U.S. military veterans. One hundred participants were randomized, with 94 included in the reported analysis. [17]

After a placebo lead-in, the four-week treatment regimen increased from 100 mg daily during the first week to 300 mg during the second week and 500 mg during the final two weeks. Compared with placebo, pregnenolone produced a statistically significant but modest reduction in pain intensity. The adjusted between-group difference was approximately 0.56 points on a 0–10 daily pain scale and 0.70 points on a recalled-pain measure. [17]

This result is intriguing because it suggests that pregnenolone may influence pain processing, possibly through neurosteroid pathways, rather than functioning simply as another conventional anti-inflammatory drug. The mechanism was not established by the trial, however, and the findings need replication.

It is also important to distinguish chronic low back pain from rheumatoid arthritis. The 2020 study did not demonstrate that pregnenolone reverses autoimmune inflammation, prevents joint destruction, or substitutes for disease-modifying treatment.

The historical and modern research together provide a reason to continue investigating pregnenolone’s possible effects on pain, but not enough evidence to establish it as an arthritis therapy.

Pregnenolone Deficiency: What Are the Symptoms?

People researching pregnenolone frequently encounter lists of symptoms attributed to low levels. These commonly include fatigue, mental fog, difficulty concentrating, low mood, poor stress tolerance, disturbed sleep, and reduced libido.

The problem is that these symptoms are extremely nonspecific. They may occur with thyroid disorders, anemia, sleep problems, nutritional deficiencies, depression, medication effects, adrenal disease, or many other conditions. There is currently no widely accepted clinical syndrome of isolated pregnenolone deficiency that can be diagnosed from these symptoms alone.

That does not mean pregnenolone production is irrelevant to health. Abnormal steroid synthesis occurs in recognized endocrine disorders, including certain rare forms of congenital adrenal hyperplasia. But these conditions involve specific enzyme abnormalities and characteristic hormonal patterns, not merely a general collection of symptoms such as fatigue and poor concentration.

For example, adrenal insufficiency may produce profound fatigue, weakness, weight loss, dizziness, low blood pressure, and sometimes salt craving. Because adrenal insufficiency can become medically serious, these symptoms require appropriate clinical evaluation rather than an assumption that pregnenolone supplementation will solve the problem.

Does Pregnenolone Decline with Age?

Another widely repeated claim is that pregnenolone declines dramatically as people grow older. While the age-related decline of DHEA sulfate is well documented, the evidence for a comparable, consistent decline in pregnenolone is less clear.

A 1981 study examined circulating steroid concentrations in 155 postmenopausal women aged 34–83 and found that pregnenolone did not change significantly across the ages studied. [18] A later investigation published in 1999, involving 233 healthy participants aged 2–66, identified age-related and sex-related patterns in pregnenolone and 17-hydroxypregnenolone concentrations. [19]

These studies examined different populations using older laboratory methods, and neither resolves every question about pregnenolone changes across the lifespan. They do suggest that statements about dramatic, universal age-related pregnenolone depletion are more confident than the available evidence supports.

Age may influence steroid hormone production, but it should not be used by itself to diagnose pregnenolone deficiency or justify supplementation.

Can Pregnenolone Be Measured?

Pregnenolone can be measured in serum using specialized laboratory techniques such as liquid chromatography–tandem mass spectrometry, commonly abbreviated LC-MS/MS.

Mayo Clinic Laboratories offers serum pregnenolone testing primarily as an ancillary investigation in evaluating uncommon forms of congenital adrenal hyperplasia, particularly when abnormalities involving 3β-hydroxysteroid dehydrogenase are suspected. Its published adult reference interval is 33–248 ng/dL, illustrating the considerable range of concentrations that may be observed in healthy adults. [20]

A pregnenolone result should therefore be interpreted in clinical context. A concentration toward the lower end of the reference interval does not establish that symptoms are caused by inadequate pregnenolone, nor does it necessarily indicate that supplementation would be helpful.

When symptoms suggest an endocrine problem, the more useful approach is to evaluate the relevant hormonal pathways rather than focus on a single precursor in isolation.

Pregnenolone Dosing: What Has Actually Been Studied?

The history of pregnenolone dosing is unusually broad. Some modern supplement products contain relatively small quantities, while clinical investigators have administered several hundred milligrams daily. This makes it especially important to distinguish historical use, research protocols, and established clinical treatment.

The World War II performance studies investigated doses of approximately 45–50 mg daily. The 2004 healthy-volunteer study by Meieran and colleagues used 15 mg and then 30 mg daily over successive two-week periods. In contrast, some historical arthritis investigations administered 100–300 mg daily, sometimes by injection rather than orally. [9, 12, 16]

More recent psychiatric and pain studies have explored substantially higher doses, frequently escalating to 500 mg daily under research supervision. The 2009 schizophrenia study reached 500 mg daily, the 2014 bipolar depression trial used a similar maximum dose, and the 2020 chronic low back pain study escalated from 100 mg to 500 mg over four weeks. [6, 13, 17]

These experimental regimens should not be interpreted as general dosing recommendations. There is currently no established therapeutic dose for pregnenolone in the treatment of ordinary fatigue, age-related hormone changes, memory complaints, or general hormone optimization.

Does Increasing the Dose Produce Greater Benefits?

Not necessarily. A 2026 exploratory analysis by Quinlan and colleagues examined stress- and alcohol-cue-provoked pain responses in participants from an eight-week randomized pilot trial involving alcohol use disorder. The original treatment groups included placebo and pregnenolone doses of 300 mg or 500 mg daily. [21]

The analysis found differing patterns of provoked pain responses across the groups. Notably, some within-group increases in pain were absent at 300 mg but observed under certain conditions in the placebo and 500-mg groups. These exploratory findings do not prove that 300 mg is superior to 500 mg, but they illustrate why a simple assumption that higher doses must work better may be misleading.

Pregnenolone is an upstream steroid precursor, and increasing its availability may affect several metabolic pathways. Those pathways are regulated differently in different tissues, making individual responses difficult to predict.

Can Pregnenolone Be Used Instead of Progesterone?

This question deserves special attention because pregnenolone and progesterone are frequently discussed together.

Pregnenolone can be converted into progesterone, and human supplementation studies have demonstrated increases in circulating progesterone and its neuroactive metabolites. However, the amount converted depends on enzyme activity, tissue-specific metabolism, and other physiological factors. [6, 13]

Someone taking pregnenolone therefore cannot assume that a particular dose will produce a predictable progesterone concentration or reproduce the clinical effects of progesterone therapy.

That distinction is important because progesterone has biological activities that should be evaluated on their own merits. The fact that one hormone precedes another in a biochemical pathway does not make them therapeutically equivalent.

What About Safety and Long-Term Use?

Pregnenolone is often marketed as a natural supplement, but natural does not mean biologically inactive. Pregnenolone is a steroid precursor, and supplementation can alter circulating concentrations of several downstream hormones and neuroactive metabolites.

Some small, short-duration clinical trials have reported generally good tolerability, including the 2020 chronic low back pain trial. Nevertheless, the available research is insufficient to establish long-term safety, particularly with sustained high-dose use or in people with complex endocrine conditions. [17]

An FDA staff assessment prepared for a 2017 Pharmacy Compounding Advisory Committee meeting reviewed clinical and safety information concerning pregnenolone. The assessment discussed possible adverse effects identified in reference sources, including headaches, insomnia, irritability, anxiety, nausea, acne, mood changes, and changes in hair growth. These are potential adverse reactions, not established rates from large controlled pregnenolone trials. (FDA assessment)

Special caution is appropriate for people with hormone-sensitive conditions, seizure disorders, or significant psychiatric conditions, as well as those already receiving hormone therapy. Pregnenolone should not be used during pregnancy or breastfeeding without specific medical guidance, because adequate safety information is lacking.

Another consideration is product quality. Pregnenolone is sold as a dietary supplement in the United States, where dietary supplements are not subject to the same premarket approval requirements as prescription drugs. Manufacturers are responsible for meeting applicable quality and labeling standards, but marketing claims should not be confused with evidence of clinical effectiveness. (FDA dietary supplement guidance)

The much higher doses used in controlled investigations should never be assumed to be appropriate for unsupervised supplementation.

Pregnenolone Deserves Another Look

Pregnenolone occupies an extraordinary position in human physiology. It begins the process that ultimately produces many of the body’s most important steroid hormones, yet it also participates in biological pathways that extend beyond conventional endocrine function.

Its production depends on cholesterol transport, mitochondrial activity, and specialized enzymes. Vitamin A signaling can influence steroidogenic machinery in experimental systems, while thyroid status is associated with changes in circulating pregnenolone sulfate and related adrenal steroids. Stress can affect reproductive hormone production, although the popular concept of pregnenolone steal oversimplifies these complex relationships.

The historical research is equally remarkable. Scientists investigated pregnenolone for mental and physical performance during World War II, physicians explored its possible usefulness in rheumatoid arthritis, and contemporary researchers have continued examining its effects on psychiatric symptoms and pain. These investigations span more than eight decades and demonstrate that pregnenolone is far from a newly discovered wellness trend.

At the same time, scientific curiosity must be distinguished from established therapeutic benefit. The available evidence does not support diagnosing pregnenolone deficiency from nonspecific symptoms, assuming age-related depletion in every individual, or using high-dose supplementation indiscriminately.

Perhaps the most important lesson is that hormone health cannot be reduced to raising or lowering one laboratory value. Pregnenolone, progesterone, cortisol, DHEA, and the sex hormones exist within a highly coordinated network of biochemical pathways. Understanding those relationships offers a more meaningful foundation for evaluating hormonal symptoms and potential treatment strategies.

Pregnenolone may have been overshadowed by the hormones produced downstream from it, but its history and biology make it a compelling subject for continued scientific investigation.

Scientific References

1. Hu J, Zhang Z, Shen W-J, Azhar S. Cellular cholesterol delivery, intracellular processing and utilization for biosynthesis of steroid hormones. Nutrition & Metabolism. 2010;7:47.
2. Manna PR, et al. Up-regulation of steroid biosynthesis by retinoid signaling: Implications for aging. Mechanisms of Ageing and Development. 2015.
3. NIH Office of Dietary Supplements. Vitamin A and Carotenoids: Health Professional Fact Sheet.
4. Tagawa N, et al. Serum dehydroepiandrosterone, dehydroepiandrosterone sulfate, and pregnenolone sulfate concentrations in patients with hyperthyroidism and hypothyroidism. Clinical Chemistry. 2000;46(4):523–528.
5. Tambones I, le Maire A. Structural Insights Into Thyroid Hormone Receptors. Endocrinology. 2025;166(1):bqae154.
6. Marx CE, et al. Proof-of-concept trial with the neurosteroid pregnenolone targeting cognitive and negative symptoms in schizophrenia. Neuropsychopharmacology. 2009;34:1885–1903.
7. Solano ME, Arck PC. Steroids, Pregnancy and Fetal Development. Frontiers in Immunology. 2019;10:3017. Published online January 2020.
8. Phumsatitpong C, Wagenmaker ER, Moenter SM. Neuroendocrine interactions of the stress and reproductive axes. Frontiers in Neuroendocrinology. 2021;63:100928.
9. Pincus G, Hoagland H. Effects of administered pregnenolone on fatiguing psychomotor performance. Journal of Aviation Medicine. 1944;15(2):98–115.
10. Hoagland H. Adventures in Biological Engineering. Science. 1944;100(2587):63–67.
11. Pincus G, Hoagland H. Effects on industrial production of the administration of Δ5-pregnenolone to factory workers. Psychosomatic Medicine. 1945;7:342–352.
12. Meieran SE, et al. Chronic pregnenolone effects in normal humans: attenuation of benzodiazepine-induced sedation. Psychoneuroendocrinology. 2004;29(4):486–500.
13. Brown ES, et al. A randomized, double-blind, placebo-controlled trial of pregnenolone for bipolar depression. Neuropsychopharmacology. 2014.
14. Freeman H, Pincus G, Johnson CW, et al. Therapeutic efficacy of Δ5-pregnenolone in rheumatoid arthritis: Preliminary observations. JAMA. 1950;142(15):1124–1128.
15. Stock JPP, McClure EC. Pregnenolone in the treatment of rheumatoid arthritis. The Lancet. 1950;2:125–128.
16. Myers GN, Ross DN. Further observations on the use of pregnenolone in rheumatoid arthritis. Annals of the Rheumatic Diseases. 1951;10(4):432–440.
17. Naylor JC, et al. Effect of Pregnenolone vs Placebo on Self-reported Chronic Low Back Pain Among US Military Veterans: A Randomized Clinical Trial. JAMA Network Open. 2020.
18. Meldrum DR, et al. Changes in circulating steroids with aging in postmenopausal women. Obstetrics & Gynecology. 1981;57(5):624–628.
19. Hill M, et al. Age relationships and sex differences in serum levels of pregnenolone and 17-hydroxypregnenolone in healthy subjects. Clinical Chemistry and Laboratory Medicine. 1999;37(4):439–447.
20. Mayo Clinic Laboratories. Pregnenolone, Serum — Test Catalog.
21. Quinlan R, Gao H, Sinha R, Milivojevic V. Effects of the neuroactive steroid precursor pregnenolone on stress- and alcohol cue-provoked pain responses in individuals with alcohol use disorder. Experimental and Clinical Psychopharmacology. 2026.

Research note: This article is a narrative discussion of selected historical investigations, clinical trials, laboratory research, and endocrine physiology. It is not a systematic review. The original 1944 aviation study has not been fully reviewed for all participant and design details.

Medical Disclaimer: This article is for educational purposes only and is not a substitute for individualized medical advice. Pregnenolone is a biologically active steroid precursor, and supplementation should be discussed with a qualified healthcare professional, particularly in the presence of endocrine disorders, hormone-sensitive conditions, psychiatric illness, pregnancy, or concurrent hormone therapy.